Business Description
Zealand Pharma AS
ISIN : US98920Y1064
Share Class Description:
ZLDPY: DRTotal Employee Number:
544Compare
Compare
Traded in other countries / regions
ZEAL.Denmark0NZU.UKZEAL.AustriaZLDPF.USA22Z.Germany IPO Date
2013-04-10Description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 34.95 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 264.37 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 18.12 | |||||
Beneish M-Score | 144.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 285.3 | |||||
3-Year Book Growth Rate | 136.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -56.82 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.63 | |||||
9-Day RSI | 57.65 | |||||
14-Day RSI | 50.52 | |||||
3-1 Month Momentum % | -2.85 | |||||
6-1 Month Momentum % | -38.13 | |||||
12-1 Month Momentum % | -23.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 37.17 | |||||
Quick Ratio | 37.17 | |||||
Cash Ratio | 35.81 | |||||
Days Inventory | 9404.54 | |||||
Days Sales Outstanding | 0.18 | |||||
Days Payable | 218666.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.1 | |||||
Shareholder Yield % | 1.67 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 100 | |||||
Operating Margin % | 75.55 | |||||
Net Margin % | 69.22 | |||||
EBITDA Margin % | 75.78 | |||||
FCF Margin % | 67.79 | |||||
OCF Margin % | 68.58 | |||||
ROE % | 46.77 | |||||
ROA % | 43.02 | |||||
ROIC % | 1514.29 | |||||
3-Year ROIIC % | 2216.41 | |||||
ROC (Joel Greenblatt) % | 4836.37 | |||||
ROCE % | 49.35 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.35 | |||||
Forward PE Ratio | 12.56 | |||||
PE Ratio without NRI | 3.29 | |||||
Price-to-Owner-Earnings | 3.59 | |||||
PS Ratio | 2.32 | |||||
PB Ratio | 1.46 | |||||
Price-to-Tangible-Book | 1.46 | |||||
Price-to-Free-Cash-Flow | 3.42 | |||||
Price-to-Operating-Cash-Flow | 3.38 | |||||
EV-to-EBIT | 0.95 | |||||
EV-to-EBITDA | 0.94 | |||||
EV-to-Revenue | 0.72 | |||||
EV-to-FCF | 1.05 | |||||
Price-to-GF-Value | 0.02 | |||||
Price-to-Projected-FCF | 1.52 | |||||
Price-to-Graham-Number | 0.46 | |||||
| Price-to-Net-Current-Asset-Value | 1.49 | |||||
| Price-to-Net-Cash | 1.55 | |||||
Earnings Yield (Greenblatt) % | 105.26 | |||||
FCF Yield % | 30.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZLDPY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zealand Pharma AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,428.973 | ||
| EPS (TTM) ($) | 2.746 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 75.82 | ||
| 14-Day RSI | 50.52 | ||
| 14-Day ATR ($) | 0.130759 | ||
| 20-Day SMA ($) | 9.3735 | ||
| 12-1 Month Momentum % | -23.02 | ||
| 52-Week Range ($) | 7.75 - 16 | ||
| Shares Outstanding (Mil) | 346.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zealand Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zealand Pharma AS Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 133 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 42 days | ||
| Goldman Sachs Global Healthcare Conference | 2026-06-09 13:20 | 9.90 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 12:45 | 9.90 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 14:00 | 9.50 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 9.50 (+0.00%) | ||
| General meeting for 2026 | 2026-03-26 21:00 | 10.19 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 19:00 | 10.19 (+0.00%) |
Show
Entries
Zealand Pharma AS Frequently Asked Questions
What is Zealand Pharma AS(ZLDPY)'s stock price today?
The current price of ZLDPY is $9.31. The 52 week high of ZLDPY is $16.00 and 52 week low is $7.75.
When is next earnings date of Zealand Pharma AS(ZLDPY)?
The next earnings date of Zealand Pharma AS(ZLDPY) is 2026-08-13.
Does Zealand Pharma AS(ZLDPY) pay dividends? If so, how much?
Zealand Pharma AS(ZLDPY) does not pay dividend.
Guru Commentaries on OTCPK:ZLDPY
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Valeritas Announces Agreement for Zealand Pharma to Acquire Business and Retain Employees | 2020-02-09 |
Articles on Zealand Pharma AS
No articles.
Headlines
See More- 1
Jun 08, 2026
Zealand Pharma tumbles 24% as weight-loss drug data sparks safety fears
Seeking Alpha • 5:27am
Jun 05, 2026
Zealand phase 2 data on petrelintide shows durable weight loss
Seeking Alpha • 4:42pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers